Key facts
- This page summarizes Anna Louise French's Form 4 filing for Jasper Therapeutics, Inc. (JSPR).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 10 Jun 2024, 18:30.
Anna Louise French - 06 Jun 2024 Form 4 Insider Report for Jasper Therapeutics, Inc. (JSPR)
- Reporting relationship
- Director
- Issuer ticker
- JSPR
- Reported as of
- 06 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Jun 2024, 18:30:25 UTC
- Prior SEC filing
- 08 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Herb Cross, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Anna Louise French filed Form 4 for Jasper Therapeutics, Inc. (JSPR) on 10 Jun 2024.
Change
- Previous filing in this sequence was filed on 08 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
JSPR
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +7,500
- Change %
- Price
- $0.000000
- Shares after
- 7,500
- Date
- 06 Jun 2024
- Ownership
- Direct
- Underlying class
- Voting Common Stock
- Underlying amount
- 7,500
- Exercise price
- $25.41
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
SEC remarks
Exhibit 24 - Power of Attorney